Cardiology - Reviews Open access

Efficacy and safety of colchicine in patients with myocardial infarction: a systematic review and meta-analysis

Authors

Published
2 September 2026
Issue
Early Access
Section
Cardiology - Reviews
DOI
10.4081/monaldi.2026.3897

Abstract

Colchicine is an anti-inflammatory drug that has emerged as a potential treatment option following myocardial infarction (MI). This meta-analysis assesses the efficacy and safety of colchicine in patients following an MI. A comprehensive literature search was performed using the Cochrane Library, ClinicalTrials.gov, Embase, and MEDLINE, covering studies from their inception to December 2025. RevMan was used to perform a random-effects meta-analysis, and forest plots were used to visualize pooled estimates. The Mantel-Haenszel method was applied to analyze dichotomous outcomes. Nine randomized control trials (RCTs) were included in this meta-analysis, including 13,834 patients. The analysis revealed that there was no statistically significant difference between colchicine and placebo groups in all-cause mortality [relative risk (RR)=0.93, confidence interval (CI)=0.78-1.11], cardiac death (RR=0.95, CI=0.73-1.22), MI (RR=0.82, CI=0.67-1.00), stroke (RR=0.64, CI=0.26-1.58), adverse events (RR=1.01, CI=0.85-1.21),  serious adverse events (RR=0.96, CI=0.87-1.05), serious gastrointestinal adverse events (RR=1.35, CI=0.94-1.95), and serious infections (RR=1.00, CI=0.62-1.62). However, there was an increased risk of diarrhea in people with colchicine compared to the placebo (RR=2.12, CI=1.35-3.32). This meta-analysis demonstrates that colchicine following an MI does not have a significant impact on cardiovascular events or major adverse events other than an increased risk of diarrhea. There is a need for more comprehensive RCTs with longer follow-up times to fully comprehend the potential cardiovascular benefits of colchicine.

Keywords

References

  1. CDC. NHANES 2015-2016 overview. Available from: https://wwwn.cdc.gov/nchs/nhanes/continuousnhanes/overview.aspx?BeginYear=2015
  2. Ridker PM. How common is residual inflammatory risk? Circ Res 2017;120:617-9. DOI: https://doi.org/10.1161/CIRCRESAHA.116.310527
  3. Ridker PM, Bhatt DL, Pradhan AD, et al. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials. Lancet 2023;401:1293-301. DOI: https://doi.org/10.1016/S0140-6736(23)00215-5
  4. Zhang FS, He QZ, Qin CH, et al. Therapeutic potential of colchicine in cardiovascular medicine: a pharmacological review. Acta Pharmacol Sin 2022;43:2173-90. DOI: https://doi.org/10.1038/s41401-021-00835-w
  5. Zhang CY, Liu S, Sui YX, Yang M. Nucleotide-binding domain, leucine-rich repeat, and pyrin domain-containing protein 3 inflammasome: from action mechanism to therapeutic target in clinical trials. World J Gastrointest Oncol 2025;17:100094. DOI: https://doi.org/10.4251/wjgo.v17.i2.100094
  6. Adler Y, Charron P, Imazio M, et al. 2015 ESC guidelines for the diagnosis and management of pericardial diseases: the Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2015;36:2921-64. DOI: https://doi.org/10.1093/eurheartj/ehv318
  7. Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol 2013;61:404-10. DOI: https://doi.org/10.1016/j.jacc.2012.10.027
  8. Younas A, Awan Z, Khan T, et al. The effect of colchicine on myocardial infarction: An updated systematic review and meta-analysis of randomized controlled trials. Curr Probl Cardiol 2025;50:102878. DOI: https://doi.org/10.1016/j.cpcardiol.2024.102878
  9. Jolly SS, d’Entremont MA, Lee SF, et al. Colchicine in acute myocardial infarction. N Engl J Med 2025;392:633-42. DOI: https://doi.org/10.1056/NEJMoa2405922
  10. Akodad M, Lattuca B, Nagot N, et al. COLIN trial: value of colchicine in the treatment of patients with acute myocardial infarction and inflammatory response. Arch Cardiovasc Dis 2017;110:395-402. DOI: https://doi.org/10.1016/j.acvd.2016.10.004
  11. Akrami M, Izadpanah P, Bazrafshan M, et al. Effects of colchicine on major adverse cardiac events in next 6-month period after acute coronary syndrome occurrence; a randomized placebo-control trial. BMC Cardiovasc Disord 2021;21:583. DOI: https://doi.org/10.1186/s12872-021-02393-9
  12. Bouleti C, Viscogliosi S, Bresson D, et al. Colchicine in acute myocardial infarction: cardiovascular events at 1-year follow up. Open Heart 2024;11:e002474. DOI: https://doi.org/10.1136/openhrt-2023-002474
  13. Deftereos S, Giannopoulos G, Angelidis C, et al. Anti-inflammatory treatment with colchicine in acute myocardial infarction. Circulation 2015;132:1395-403. DOI: https://doi.org/10.1161/CIRCULATIONAHA.115.017611
  14. Hennessy T, Soh L, Bowman M, et al. The low dose colchicine after myocardial infarction (LoDoCo-MI) study: a pilot randomized placebo controlled trial of colchicine following acute myocardial infarction. Am Heart J 2019;215:62-9. DOI: https://doi.org/10.1016/j.ahj.2019.06.003
  15. Mewton N, Roubille F, Bresson D, et al. Effect of colchicine on myocardial injury in acute myocardial infarction. Circulation 2021;144:859-69. DOI: https://doi.org/10.1161/CIRCULATIONAHA.121.056177
  16. Roubille F, Bouabdallaoui N, Kouz S, et al. Low-dose colchicine in patients with type 2 diabetes and recent myocardial infarction in the colchicine cardiovascular outcomes Trial (COLCOT). Diabetes Care 2024;47:467-70. DOI: https://doi.org/10.2337/dc23-1825
  17. Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med 2019;381:2497-505. DOI: https://doi.org/10.1056/NEJMoa1912388
  18. Chen T, Liu G, Yu B. Colchicine for coronary artery disease: a review. Front Cardiovasc Med 2022;9:892588. DOI: https://doi.org/10.3389/fcvm.2022.892588
  19. Park HJ. Anti-inflammatory effects of colchicine on coronary artery disease. Cardiovasc Prev Pharmacother 2022;4:7-12. DOI: https://doi.org/10.36011/cpp.2022.4.e5
  20. Yu M, Yang Y, Dong SL, et al. Effect of colchicine on coronary plaque stability in acute coronary syndrome as assessed by optical coherence tomography: the COLOCT randomized clinical trial. Circulation 2024;150:981-93. DOI: https://doi.org/10.1161/CIRCULATIONAHA.124.069808
  21. Shah B, Allen N, Harchandani B, et al. Effect of colchicine on platelet-platelet and platelet-leukocyte interactions: a pilot study in healthy subjects. Inflammation 2016;39:182-9. DOI: https://doi.org/10.1007/s10753-015-0237-7
  22. Diaz-Arocutipa C, Benites-Meza JK, Chambergo-Michilot D, et al. Efficacy and Safety of colchicine in post-acute myocardial infarction patients: a systematic review and meta-analysis of randomized controlled trials. Front Cardiovasc Med 2021;8:676771. DOI: https://doi.org/10.3389/fcvm.2021.676771
  23. Leung YY, Hui LLY, Kraus VB. Colchicine --- update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum 2015;45:341-50. DOI: https://doi.org/10.1016/j.semarthrit.2015.06.013
  24. Sadiq NM, Robinson KJ, Terrell JM. Colchicine. Treasure Island, FL, USA: StatPearls Publishing; 2025.

Metrics

Citations and online attention from Dimensions, Altmetric and PlumX.

PlumX Metrics

License

Copyright (c) 2026 The Author(s)

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.